Searched for
SOLOSEC DRUG
These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsThere are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...- Stocks in the news: Ambuja Cements, Wipro, Nestle, Airtel and Tata MotorsCompanies including R Systems International, Huhtamaki India and Vijay Textiles will announce their December quarter results today.
- Lupin gets USFDA nod for using specialty drug Solosec on adolescentsThe supplemental adolescent approval enhances Solosec's strong position as the first and only single-dose oral prescription antimicrobial a...
- Stocks in the news: Lupin, BHEL, Canara Bank, RBL Bank, L&T and PNBKotak Mahindra Bank, L&T, Vedanta, Britannia, Dr Reddy's Labs, Marico, Info Edge, Bharat Electronics, Au SFB and Oberoi Realty are among th...
- Lupin partners with Exeltis for marketing its specialty drug Solosec in USET reported in October about Lupin trying to find a marketing partner or even be open to the idea of possible sale of its key specialty dru...
- Lupin skids as failed USFDA specifications lead to recalls of 2 drugsThe company’s scrip fell to a low of Rs 937.15 as against Rs 951.80 at previous close on the National Stock Exchange.
- Lupin says trying to find marketing partner, or open to possible sale of specialty drug SolosecIndian drug makers like Lupin, Dr Reddy's, Sun Pharma, among others have placed bets on specialty drugs that are protected by patents as st...
- Lupin Q2 results: Firms posts Rs 2,095 crore loss due to one-off impairmentsDuring the quarter, the company booked a provision of Rs 1879.6 crore towards litigation and settlement related to diabetic drug Glumetza c...
- Stocks in the news: Banks, Vodafone Idea, Dixon, Lupin and NMDCBanking stocks, telecom service providers and IT hardware manufacturing counters will be at the focus of investors. A few auto companies ma...
- Lupin arm gets supplemental new drug application approval from US regulator for SolosecThe drug was approved in the US in 2017 for the treatment of bacterial vaginosis in adult women, the company said.
- Q4 earning preview: Pharma pack up for good show, may go unscathed from virus hitInvestors may keenly follow Sun Pharma earnings for updates on Halol OAI.
- Lupin aims to launch new products across geographies this fiscal"Looking ahead, FY2020 is an exciting year for Lupin as we plan to bring our first biosimilar to market," company said.
- Lupin gains 3% on Credit Suisse upgrade, Nomura’s buy ratingNomura has maintained a ‘buy’ rating on Lupin with a target price of Rs 1,017.
- Lupin still on track to meet $800-million FY19 sales target: Ramesh SwaminathanThings not as bad as they were in the past and should be looking better, says Lupin CFO.
- For every rupee depreciation, we expect to add Rs 40 cr to bottom line: Ramesh Swaminathan, Lupin“Between 25% and 30% of our total exposures are hedged.”
- Lupin to launch nearly 30 products in US market in FY18The drug firm is banking on the introduction of complex generics and biosimilars in the US to maintain its top five position in the market.
- Complex generics, biosimilars & specialty to be growth drivers: LupinWhile sustaining and growing its presence in the generics segment, Lupin is planning to invest heavily in developing high barrier products ...
- Lupin makes impairment provision for GavisLupin took a hit worth Rs 1,464.35 crore on US-based Gavis, which it acquired in 2015 for $880 million (Rs 5,610 crore then).
- We expect domestic business to grow at 15%: S Ramesh, LupinI expect the price erosion to continue in America in the first two quarters at least for the current year before it stabilises around 8-10%.
- Lupin's US arm takes over Symbiomix TherapeuticsLupin had entered into an arrangement to acquire the company earlier this year.
Load More
